Discover
OPTN
OptiNose, Inc.
9.60
undefined x undefined
undefined x undefined
bid
ask
+
9.60
0.00%
07:00 PM
| Ytd | 43.71% | |
| 1y | -46.67% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -4.65 |
| Beta | N/A | Short Ratio | 6.05 | Inst. Own | 78.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 3.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.05 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | -0.08 | -0.07 | 0.01 | 12.50% |
| 2024-08-08 | 2024-06 | -0.08 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.1 | -0.12 | -0.02 | -20.00% |
| 2024-05-14 | 2024-03 | -0.1 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.1 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-13 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-15 | Lake Street | Upgrade | Buy | Buy |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-18 | Lake Street | Upgrade | Buy | Buy |
Profile
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-06 | KOHLER TERRY | Chief Financial Officer | 150.00K | Stock Award(Grant) |
| 2024-07-16 | KRICK ANTHONY J | Officer | 140.76K | Sale |
| 2024-12-16 | MAHMOUD RAMY A | Chief Executive Officer | 1.37M | Sale |
| 2024-12-16 | MARINO MICHAEL F III | Officer | 544.19K | Sale |
| 2023-01-12 | MILLER PETER K | Chief Executive Officer | 957.80K | Sale |
| 2024-02-27 | SPENCE PAUL JR. | Officer | 252.68K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 16.54M | 6.92M | 10.97% |
| 2024-09-29 | MVM Partners, LLC | 14.61M | 6.11M | 9.68% |
| 2024-09-29 | Nantahala Capital Management, LLC | 14.36M | 6.01M | 9.52% |
| 2024-09-29 | Great Point Partners LLC | 12.86M | 5.38M | 8.53% |
| 2024-09-29 | Rosalind Advisors, Inc. | 8.29M | 3.47M | 5.49% |
| 2024-09-29 | Stonepine Capital Management, LLC | 5.69M | 2.38M | 3.77% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Growth Company Fund | 5.58M | 2.34M | 3.70% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.65M | 1.11M | 1.75% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 1.89M | 789.90K | 1.25% |
| 2024-08-30 | MFS New Discovery Fund | 1.82M | 760.00K | 1.20% |
| 2024-10-30 | Fidelity Series Growth Company Fund | 1.58M | 662.48K | 1.05% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.03M | 431.89K | 0.68% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2024-12-31 |